[go: up one dir, main page]

WO2002045753A3 - Preparation pharmaceutique a base de gepirone pour administration par voie orale - Google Patents

Preparation pharmaceutique a base de gepirone pour administration par voie orale Download PDF

Info

Publication number
WO2002045753A3
WO2002045753A3 PCT/EP2001/014189 EP0114189W WO0245753A3 WO 2002045753 A3 WO2002045753 A3 WO 2002045753A3 EP 0114189 W EP0114189 W EP 0114189W WO 0245753 A3 WO0245753 A3 WO 0245753A3
Authority
WO
WIPO (PCT)
Prior art keywords
amount
gepirone
extended release
formulation
release formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/014189
Other languages
English (en)
Other versions
WO2002045753A2 (fr
Inventor
Johannes Gerardus Jos Egberink
John Francis Engelhart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL15585501A priority Critical patent/IL155855A0/xx
Priority to JP2002547535A priority patent/JP2004517083A/ja
Priority to BR0115976-3A priority patent/BR0115976A/pt
Priority to MXPA03005099A priority patent/MXPA03005099A/es
Priority to EP01995688A priority patent/EP1343504A2/fr
Priority to CA002436692A priority patent/CA2436692A1/fr
Priority to HU0401021A priority patent/HUP0401021A2/hu
Priority to AU2002226371A priority patent/AU2002226371A1/en
Priority to SK694-2003A priority patent/SK6942003A3/sk
Priority to KR10-2003-7007555A priority patent/KR20040018314A/ko
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Priority to PL01362445A priority patent/PL362445A1/xx
Publication of WO2002045753A2 publication Critical patent/WO2002045753A2/fr
Publication of WO2002045753A3 publication Critical patent/WO2002045753A3/fr
Priority to NO20032581A priority patent/NO20032581D0/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une préparation pharmaceutique destinée à être administrée par voie orale, présentant des propriétés de libération prolongée et renfermant une dose d'hydrochlorure de gépirone, une dose d'une matrice polymère cellulosique et une dose de cellulose microcristalline. Cette préparation est caractérisée par le fait que la dose pharmaceutiquement acceptable de la matrice polymère cellulosique représente 70 à 85 % en masse, la dose de liant d'hydrate de carbone représente 7 à 10 % en masse et la dose d'hydrochlorure de gépirone représente 13 à 21 % en masse. Cette préparation est utile pour le traitement de la dépression ou d'un trouble du système nerveux central associé, la préparation à base de gépirone étant administrée sous forme de dose quotidienne unique pour une libération prolongée de gépirone.
PCT/EP2001/014189 2000-12-08 2001-11-30 Preparation pharmaceutique a base de gepirone pour administration par voie orale Ceased WO2002045753A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SK694-2003A SK6942003A3 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone
BR0115976-3A BR0115976A (pt) 2000-12-08 2001-11-30 Formulação farmacêutica, e, tratamento para depressão ou para uma desordem relacionada com o sistema nervoso central
MXPA03005099A MXPA03005099A (es) 2000-12-08 2001-11-30 Formulacion de liberacion extendida oral de gepirona.
EP01995688A EP1343504A2 (fr) 2000-12-08 2001-11-30 Preparation pharmaceutique a base de gepirone pour administration par voie orale
CA002436692A CA2436692A1 (fr) 2000-12-08 2001-11-30 Preparation pharmaceutique a base de gepirone pour administration par voie orale
HU0401021A HUP0401021A2 (hu) 2000-12-08 2001-11-30 Gepiront tartalmazó gyógyászati készítmény orális beadásra
AU2002226371A AU2002226371A1 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone
IL15585501A IL155855A0 (en) 2000-12-08 2001-11-30 Pharmaceutical formulation of gepirone for oral administration
JP2002547535A JP2004517083A (ja) 2000-12-08 2001-11-30 ジェピロンの経口用持続放出性製剤
KR10-2003-7007555A KR20040018314A (ko) 2000-12-08 2001-11-30 게피론을 함유하는 경구 투여용 연장 방출형 제제
PL01362445A PL362445A1 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone
NO20032581A NO20032581D0 (no) 2000-12-08 2003-06-06 Farmasöytisk formulering av gepiron for oral administrering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00204388 2000-12-08
EP00204388.3 2000-12-08

Publications (2)

Publication Number Publication Date
WO2002045753A2 WO2002045753A2 (fr) 2002-06-13
WO2002045753A3 true WO2002045753A3 (fr) 2002-08-29

Family

ID=8172397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/014189 Ceased WO2002045753A2 (fr) 2000-12-08 2001-11-30 Preparation pharmaceutique a base de gepirone pour administration par voie orale

Country Status (19)

Country Link
EP (1) EP1343504A2 (fr)
JP (1) JP2004517083A (fr)
KR (1) KR20040018314A (fr)
CN (1) CN1479620A (fr)
AR (1) AR031461A1 (fr)
AU (1) AU2002226371A1 (fr)
BR (1) BR0115976A (fr)
CA (1) CA2436692A1 (fr)
CZ (1) CZ20031589A3 (fr)
EC (1) ECSP034627A (fr)
HU (1) HUP0401021A2 (fr)
IL (1) IL155855A0 (fr)
MX (1) MXPA03005099A (fr)
NO (1) NO20032581D0 (fr)
PL (1) PL362445A1 (fr)
RU (1) RU2003120446A (fr)
SK (1) SK6942003A3 (fr)
WO (1) WO2002045753A2 (fr)
ZA (1) ZA200303915B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545469A1 (fr) * 2002-09-24 2005-06-29 Akzo Nobel N.V. Methode permettant d'apporter des ameliorations a des comprimes pharmaceutiques comprenant une matrice a base d'ether de cellulose
WO2006052227A1 (fr) * 2004-11-05 2006-05-18 Fabre-Kramer Holdings, Inc. Preparation de gepirone a liberation prolongee hautement dosee
MY198454A (en) * 2017-07-26 2023-08-29 Abbott Lab Nutritional Tablets and Methods of Making the Same
CN109745323A (zh) * 2017-11-01 2019-05-14 四川科瑞德制药股份有限公司 氮哌酮类化合物提高副交感神经活性的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700680A1 (fr) * 1994-09-06 1996-03-13 Bristol-Myers Squibb Company Formulations contenant de gepirone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700680A1 (fr) * 1994-09-06 1996-03-13 Bristol-Myers Squibb Company Formulations contenant de gepirone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEIGER A.D.: "A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.", PSYCHOPHARMACOLOGY BULLETIN, (1996) 32/4 (659-665)., XP001069219 *
WILCOX C.S.: "A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients", PSYCHOPHARMACOLOGY BULLETIN, (1996) 32/3 (335-342)., XP001069224 *

Also Published As

Publication number Publication date
WO2002045753A2 (fr) 2002-06-13
BR0115976A (pt) 2003-12-30
CA2436692A1 (fr) 2002-06-13
EP1343504A2 (fr) 2003-09-17
CN1479620A (zh) 2004-03-03
PL362445A1 (en) 2004-11-02
JP2004517083A (ja) 2004-06-10
CZ20031589A3 (cs) 2003-11-12
AR031461A1 (es) 2003-09-24
RU2003120446A (ru) 2005-02-20
NO20032581L (no) 2003-06-06
AU2002226371A1 (en) 2002-06-18
ECSP034627A (es) 2004-09-28
NO20032581D0 (no) 2003-06-06
IL155855A0 (en) 2003-12-23
HUP0401021A2 (hu) 2004-09-28
SK6942003A3 (en) 2003-10-07
KR20040018314A (ko) 2004-03-03
ZA200303915B (en) 2004-08-20
MXPA03005099A (es) 2004-02-12

Similar Documents

Publication Publication Date Title
EP1649851A3 (fr) Amidon prégélatinisé dans une formulation à libération contrôlée
CA2264238A1 (fr) Forme galenique a liberation prolongee de milnacipran
WO2004010998A8 (fr) Comprime a liberation prolongee comprenant de la reboxetine
WO2003013433A3 (fr) Formulations d'antagoniste sequestre
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
HK1042427A1 (zh) 用於高溶度药物的持续释放基质方法
MXPA02005562A (es) Superdesintegrante farmaceutico.
WO2004098564A3 (fr) Nanoparticules biodegradables integrant des medicaments hautement hydrophiles et positivement charges
CA2157323A1 (fr) Forme posologique de la gepirone
US4657757A (en) Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
AU5673399A (en) Compositions and methods for treating intracellular infections
WO2002011694A3 (fr) Compositions et formes posologiques en vue d'une application dans la cavite orale dans le cadre du traitement de mycoses
WO2002045753A3 (fr) Preparation pharmaceutique a base de gepirone pour administration par voie orale
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
US6524617B1 (en) Synergistic filler composition
US6589996B2 (en) Treatment of disorders relating to the serotonergic system
RU2002128010A (ru) Препараты для перорального введения с замедленным высвобождением
WO2008060890A3 (fr) Forme posologique orale de darusentan
EP0761209A3 (fr) Formulations de la ranitidine à libération commandée
AU758880B2 (en) Timed release tablet comprising naproxen and pseudoephedrine
WO2002017877A3 (fr) Compositions pour granules pharmaceutiques a liberation controlee destinees a limiter les effets secondaires de medicaments
CA2403674A1 (fr) Utilisation de triiodothyronine pour le traitement de l'insuffisance cardiaque congestive
US6099860A (en) Controlled release oral preparation with naproxen sodium and pseudoephedrine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PH PL RO RU SG SI SK SL TR TT UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2003-500452

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2001995688

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 155855

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/03915

Country of ref document: ZA

Ref document number: 526014

Country of ref document: NZ

Ref document number: 200303915

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002226371

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 03047109

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2436692

Country of ref document: CA

Ref document number: 1020037007555

Country of ref document: KR

Ref document number: 6942003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 018201792

Country of ref document: CN

Ref document number: 2002547535

Country of ref document: JP

Ref document number: PA/a/2003/005099

Country of ref document: MX

Ref document number: 899/CHENP/2003

Country of ref document: IN

Ref document number: PV2003-1589

Country of ref document: CZ

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 2001995688

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-1589

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020037007555

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2003-1589

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001995688

Country of ref document: EP